News

Apr 15

20MED THERAPEUTICS PUBLISHES POSITIVE IN VIVO EFFICACY DATA OF A MRNA INFLUENZA VACCINE USING ITS PROPRIETARY POLYMERIC NANOPARTICLE TECHNOLOGY

Preclinical data underscores the potential to deliver a strong protective effect using Polymeric Nanoparticles (PNPs), an alternative to...

Apr 13

Come and meet us at BIO2024

Meet the 20Med Therapeutics team in San Diego during the BIO International Convention to discuss partnering opportunities around our PNP...

Nov 29, 2023

20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the...